Vertex (VRTX) SVP Kristen Ambrose Sells 357 Shares

What Happened
Kristen Ambrose, SVP and Chief Accounting Officer of Vertex Pharmaceuticals (VRTX), sold 357 shares on 2026-02-26 at $483.36 per share for a total of $172,560. The transaction is reported as a sale (open‑market or private sale) and was executed under a pre‑arranged company trading plan.

Key Details

• Transaction date: 2026-02-26
• Price: $483.36 per share; Shares sold: 357; Total value: $172,560
• Filing date: Form 4 filed 2026-03-02 reporting the Feb 26 trade
• Post-transaction shares owned: Not specified in the provided excerpt
• Footnote: Sale made pursuant to a company‑approved Rule 10b5‑1 trading plan entered 08/08/2025
• Filing timeliness: No late‑filing flag provided in the excerpt; check the full SEC filing for timeliness status

Context
A 10b5‑1 plan allows executives to sell predetermined amounts at set times and is commonly used to avoid perceptions of trading on insider information. Such routine planned sales are usually less informative about an insider’s current view of the company than ad‑hoc purchases. Retail investors should treat this as a routine, pre‑scheduled sale unless additional filings or context indicate otherwise.